NCT02616640 2024-09-19A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCelgenePhase 1 Completed114 enrolled